We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) to Raise Debt for Best Doctors Acquisition
Read MoreHide Full Article
Teladoc, Inc. (TDOC - Free Report) announced recently that it would offer senior notes worth $200 million, with the year of maturity fixed as 2022. The company also expects to provide the initial purchaser an option to buy up to an additional $30 million aggregate principal amount of notes on the same terms and conditions, solely to cover over-allotments.
Teladoc will use proceeds from the offering to fund a portion of the cash payable for its recently announced acquisition of Best Doctors Holdings, Inc., the world’s leading expert medical consultation company. The acquisition primarily aims at improving health outcomes for the most complex, critical and costly medical issues. Teladoc basically intends to create a new paradigm for patients to access care by delivering a powerful connected care platform.
This apart, the company also intends to refinance existing indebtedness and to pay related fees and expenses. The remaining proceeds will be utilized for working capital and other general corporate purposes.
Teladoc’s strategic initiatives to improve profitability and reduce liabilities make it well positioned for future growth. Year to date, shares of Teladoc have rallied 98% outperforming the Zacks categorized Medical Service industry’s gain of only 6%.
At the end of first-quarter 2017, Teladoc had $42 million of long-term debt, up 68% from the year-ago quarter and unchanged from year-end 2016.. Its interest expense also rose 63% year over year but declined 46% from year-end 2016.
Align Technology, a medical dental supplies company, topped estimates in each of the last four quarters with an average beat of 59.23%.
Inogen is a medical instruments seller, which delivered positive surprises in each of the last four quarters with an average beat of 82.42%.
EDAP TMS also posted positive surprises in two of the last four quarters with an average beat of 366.67%.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) to Raise Debt for Best Doctors Acquisition
Teladoc, Inc. (TDOC - Free Report) announced recently that it would offer senior notes worth $200 million, with the year of maturity fixed as 2022. The company also expects to provide the initial purchaser an option to buy up to an additional $30 million aggregate principal amount of notes on the same terms and conditions, solely to cover over-allotments.
Teladoc will use proceeds from the offering to fund a portion of the cash payable for its recently announced acquisition of Best Doctors Holdings, Inc., the world’s leading expert medical consultation company. The acquisition primarily aims at improving health outcomes for the most complex, critical and costly medical issues. Teladoc basically intends to create a new paradigm for patients to access care by delivering a powerful connected care platform.
This apart, the company also intends to refinance existing indebtedness and to pay related fees and expenses. The remaining proceeds will be utilized for working capital and other general corporate purposes.
Teladoc’s strategic initiatives to improve profitability and reduce liabilities make it well positioned for future growth. Year to date, shares of Teladoc have rallied 98% outperforming the Zacks categorized Medical Service industry’s gain of only 6%.
At the end of first-quarter 2017, Teladoc had $42 million of long-term debt, up 68% from the year-ago quarter and unchanged from year-end 2016.. Its interest expense also rose 63% year over year but declined 46% from year-end 2016.
Zacks Rank and Stocks to Consider
Teladoc presently has a Zacks Rank #3 (Hold). Investors can consider some better-ranked stocks like Align Technology, Inc. (ALGN - Free Report) , EDAP TMS S.A. (EDAP - Free Report) and Inogen Inc. (INGN - Free Report) . All of the stocks sport a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, a medical dental supplies company, topped estimates in each of the last four quarters with an average beat of 59.23%.
Inogen is a medical instruments seller, which delivered positive surprises in each of the last four quarters with an average beat of 82.42%.
EDAP TMS also posted positive surprises in two of the last four quarters with an average beat of 366.67%.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>